LB Pharmaceuticals Q1 net loss widens on higher R&D costs

LB Pharmaceuticals

12/05/2026 21:17

Overview

US biopharmaceutical firm's Q1 net loss widened amid higher R&D and administrative expenses

Company initiated two late-stage clinical trials for LB-102 in schizophrenia and bipolar depression

Cash position rose to $365.6 mln, expected to fund operations into Q2 2029

Outlook

Company expects topline data from Phase 3 NOVA-2 trial in schizophrenia in H2 2027

Topline data from ILLUMINATE-1 trial in bipolar depression expected in Q1 2028

Cash position expected to fund operations into Q2 2029

Result Drivers

CLINICAL TRIAL EXPENSES - Co said higher R&D costs were mainly due to increased clinical trial spending for LB-102 in schizophrenia and bipolar depression

ADMINISTRATIVE EXPENSES - Co said higher G&A costs were due to increased headcount, stock-based compensation, and professional fees

Company press release: ID:nGNX9KDZLc

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$19.05 mln
Q1 Basic EPS
-$0.67
Q1 Operating Income
-$22.10 mln
Q1 Pretax Profit
-$19.05 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for LB Pharmaceuticals Inc is $38.00, about 16.2% above its May 11 closing price of $32.70

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)